| Trial | Updated / Type |
Status | Phase | Were Results Reported |
Reported Actual Enrollment |
(MeSH) Terms |
Why Stopped
Limitations And Caveats |
Annotator decisions |
|---|---|---|---|---|---|---|---|---|
| NCT00380874 Details | 2021-02-11 Interventional | 4 | 64 | Pregabalin Peripheral Nerv… Chemotherapy-In… | See detailed description for termination reason Due to lack of symptom emergence, enrollment was halted, and endpoint modified because primary assumptions upon which it was powered (emergence of symptomatology) were not met, and not all endpoints were able to be reliably analyzed. | |||
| NCT03368859 2017-003669-87 Details | 2021-02-09 Interventional | 2 | 70 | Bevacizumab Fluorouracil Irinotecan Leucovorin Colorectal Neop… Cancer | Study may continue - | |||
| NCT02697162 Details | 2021-02-09 Interventional | 2/3 | 0 | Anti-Infective … Octenidine Catheter-Relate… Infections Urinary Bladder… Neurogenic Blad… | Withdrawal of research institution from participating - | |||
| NCT04416399 Details | 2021-02-08 Interventional | 2 | 146 | Budesonide COVID-19 Coronavirus Inf… Infections Coronavirus Inf… | Independent statistical review advice - | |||
| NCT00960804 Details | 2021-02-08 Interventional | 3 | 21 | Tanezumab Osteoarthritis | See termination reason in detailed description. Due to FDA-imposed clinical hold, enrollment stopped prematurely, thus inadequate power to fulfill primary objectives.Efficacy data beyond Week 32 not collected.Change in planned analysis added results of >=70%, 90% reduction in WOMAC pain subscale. | |||
| NCT04382625 Details | 2021-02-05 Interventional | 4 | 0 | Hydroxychloroqu… COVID-19 Pneumonia SARS-CoV-2 Pneu… | Secondary to other study results, suspended for a scientific review - | |||
| NCT02240160 2013-004459-19 Details | 2021-02-05 Interventional | 1 | 6 | Nabiximols Healthy Volunte… | - - | |||
| NCT03998592 Details | 2021-02-04 Interventional | 1 | 0 | Vaccines Rheumatic Fever | Agreement between interested partied ended - | |||
| NCT03680911 Details | 2021-02-04 Interventional | 3 | 7 | Acetylcysteine N-monoacetylcys… Anosmia Craniocerebral … Wounds and Inju… Head Trauma | Poor participant compliance - | |||
| NCT03319823 Details | 2021-02-04 Interventional | 4 | 0 | Sodium Chloride… Hypertension Nocturia High Blood Pres… | Due to the Pandemic, we decided to end this study. - | |||
| NCT00863772 Details | 2021-02-04 Interventional | 3 | 220 | Tanezumab Osteoarthritis | See termination reason in detailed description. Due to US FDA imposed clinical hold (effective 23 June 2010), study was terminated early and planned sample size was not achieved. Due to change in planned analysis pre-specified outcome measure 'time to discontinuation due to lack of efficacy' was removed. | |||
| NCT02893332 Details | 2021-02-03 Interventional | 3 | - | Erlotinib Hydro… Gefitinib Adenocarcinoma Adenocarcinoma … Stage IV EGFR M… | After interim analysis, IRB recommend termination. - | |||
| NCT00750919 2007-005237-10 Details | 2021-02-02 Interventional | 3 | 184 | Mirtazapine Dyssomnias Mental Disorder… Parasomnias Sleep Disorders… Sleep Initiatio… Sleep Wake Diso… Sleep Disorders | This trial was stopped prematurely due to the Sponsor's decision not to continue the
development of esmertazapine for this indication. This study was terminated due to the Sponsor's decision not to continue development of esmertazapine for this indication. | |||
| NCT00638157 Details | 2021-02-02 Interventional | 4 | 24 | Daptomycin Gentamicins Endocarditis Endocarditis, B… Infective Endoc… | commitment completed As the study was terminated prematurely, conclusions that can be drawn from the efficacy results are limited. | |||
| NCT00584779 Details | 2021-02-02 Interventional | 4 | 8 | Gabapentin Renal Insuffici… PK Properties O… | See detailed description for termination reason - | |||
| NCT04729088 Details | 2021-02-01 Interventional | 1 | 0 | Isosorbide Isosorbide Dini… Isosorbide-5-mo… Healthy Subject… Pharmacokinetic… | The sponsor will no longer develop the experimental drug. - | |||
| NCT03721679 Details | 2021-02-01 Interventional | 1/2 | [3 Refs] | 7 | Atezolizumab Durvalumab Nivolumab Pembrolizumab Poly ICLC Solid Cancer | Recruiting target patients is intermittent making it impracticable to enroll the required study
sample. The administrative responsibilities have been met with extraordinary challenges.
Current funding does not match the incurring costs. - | ||
| NCT03515707 Details | 2021-02-01 Interventional | 2 | 0 | Busulfan Etoposide Etoposide phosp… Podophyllotoxin Leukemia Leukemia, Myelo… Leukemia, Myelo… Neoplasm, Resid… Acute Myeloid L… Minimal Residua… | PI recommended closure - | |||
| NCT03484650 Details | 2021-02-01 Interventional | 3 | 0 | Lidocaine Hernia, Ventral Pain, Postopera… Post Operative … | Lack of available resources to complete study - | |||
| NCT02730091 Details | 2021-02-01 Interventional | 3 | 98 | Anastrozole Letrozole Vinorelbine Breast Neoplasm… Breast Cancer | - - |